Related Experiment Video
Updated: Jun 28, 2026
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Evolving paradigms in cardiovascular pharmacology: advances and clinical significance
1Department of Life Sciences, School of Biosciences and Technology, Galgotias University, Greater Noida, Uttar Pradesh, 203201, India.
Insights
This review details advances in cardiovascular drugs, including their mechanisms, pharmacokinetics, and clinical uses. It also explores how nanoscience and nanoparticles offer new, effective treatments for cardiovascular diseases, improving patient outcomes.
Area of Science:
- Pharmacology
- Nanotechnology
- Cardiovascular Medicine
Background:
- Cardiovascular diseases (CVDs) are a major cause of death globally.
- Cardiovascular drugs are widely prescribed for conditions like hypertension, heart failure, and arrhythmias.
- Recent decades have seen significant progress in developing novel cardiovascular therapies.
Purpose of the Study:
- To provide a comprehensive overview of recent advancements in cardiovascular drug therapy.
- To discuss the pharmacokinetics, pharmacodynamics, and clinical implications of key cardiovascular medications.
- To highlight the emerging role of nanoscience and nanoparticles in treating CVDs.
Main Methods:
- Review of current literature on cardiovascular drug therapy.
- Analysis of pharmacokinetics and pharmacodynamics of essential cardiovascular drugs.
- Exploration of nanotechnology applications in cardiovascular medicine.
Main Results:
- Essential cardiovascular drugs discussed include diuretics, ACEIs, beta-blockers, ARBs, calcium channel blockers, and Digoxin.
- Nanoscience and nanoparticles show promise in enhancing treatment efficacy and reducing side effects for CVDs.
- Nanotechnology may effectively treat over 50% of cardiovascular conditions due to improved specificity.
Conclusions:
- Significant progress has been made in cardiovascular drug development.
- Nanoscience offers a promising frontier for more effective and targeted cardiovascular disease treatment.
- Integrating nanotechnology into cardiovascular therapy could revolutionize patient care and prognosis.
Abstract:
Cardiovascular disease is the leading cause of morbidity and mortality among both the elderly and the young, making cardiovascular drugs the most commonly prescribed medications for these populations. Cardiovascular conditions such as arrhythmias, coronary artery disease, hyperlipidemia, heart failure, and arterial hypertension are managed with these drugs. Over the past few decades, significant advances have been made in developing cardiovascular medications to prevent and treat various diseases. This review provides a comprehensive overview of recent advances in cardiovascular drug therapy, focusing on several key drugs and their pharmacokinetics and pharmacodynamics, including absorption, excretion, metabolism, and distribution. It highlights the mechanisms of action, routes of administration, side effects, and clinical implications of essential cardiovascular drugs, such as diuretics, angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, angiotensin II receptor blockers (ARBs), calcium channel blockers, and Digoxin. Additionally, the paper discusses the use of nanoscience and nanoparticles in the effective treatment of cardiovascular diseases, highlighting their role in reducing side effects and improving prognosis. Nanoparticles are gaining significant attention for the treatment of cardiovascular conditions due to their greater sensitivity and specificity. Reports indicate that nanotechnology or nanoscience can effectively treat over 50% of cardiovascular conditions.
Related Concept Videos
01:21Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers